Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 242,300 shares, a drop of 16.8% from the December 15th total of 291,400 shares. Based on an average daily volume of 144,800 shares, the short-interest ratio is presently 1.7 days.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Oramed Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ:ORMP traded down $0.02 during midday trading on Thursday, hitting $2.32. The company's stock had a trading volume of 74,588 shares, compared to its average volume of 97,629. The stock's 50 day simple moving average is $2.38 and its 200 day simple moving average is $2.41. The stock has a market capitalization of $93.52 million, a price-to-earnings ratio of 21.09 and a beta of 1.67. Oramed Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $3.67.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORMP. Marquette Asset Management LLC bought a new stake in shares of Oramed Pharmaceuticals in the fourth quarter valued at approximately $81,000. XTX Topco Ltd raised its stake in Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 9,242 shares during the last quarter. Murchinson Ltd. boosted its holdings in Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company's stock valued at $4,170,000 after purchasing an additional 8,889 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals in the 3rd quarter valued at $272,000. Finally, BML Capital Management LLC grew its position in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock worth $5,334,000 after purchasing an additional 837,153 shares during the last quarter. Institutional investors and hedge funds own 12.73% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.